The natural history and pathophysiology of treatment resistant schizophrenia
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Defining treatment resistance among schizophrenia patients is problematic since most patients experience persistent morbidity over the course of their illness and full remissions are infrequent. In addition, the level of response to antipsychotic medication is not an immutable feature of the patient's illness that is present at its onset; rather, it can change over the course of the illness (usually unidirectionally with patients becoming less responsive to treatment) and is determined by various modifying factors. Although treatment resistance may be an enduring feature of a patient, present at illness onset and throughout, more commonly it develops over the course of patients' illnesses. Evidence from both retrospective and prospective studies suggests that a longer duration of untreated psychosis in the early stage of schizophrenia is associated with a longer time to remission and a lower level of recovery, a greater likelihood of relapse and a worse overall outcome. The pattern of deterioration observed is analogous to a well replicated neurobiologic phenomenon, termed behavioral sensitization. In sensitized animals a pathologic behavioral process emerges whereby the response to a pharmacologic or stress challenge is progressively increased in proportion to the number of pretreatments. Thus, endogenous neurochemical sensitization resulting from the inability to regulate presynaptic dopamine release in the limbic striatum may be a useful way to conceptualize the continuum of response-refractoriness that is clearly evident in schizophrenia patients. Most importantly, early detection, intervention and optimal maintenance treatment may improve the long term course of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even when patients are compliant to psychopharmaceutical treatment, symptoms, especially negative symptoms, often persist,2,6 and about 30% of patients are therapy refractory.7”
From Mindfulness-and acceptance-based interventions for psychosis: A systematic review and meta-analysis (2016) · cites this paper as [7]
In the citing paper
“While psychopharmacological treatment is the most important intervention for psychosis, its effectiveness on negative symptoms is limited6 and a considerable number of patients are therapy refractory.7”
From Mindfulness-and acceptance-based interventions for psychosis: A systematic review and meta-analysis (2016) · cites this paper as [7]
Citations
Cites
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Dementia Praecox and Paraphrenia.
(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-6-1058_8 · Cited by 2,901
Synaptic density in human frontal cortex —Developmental changes and effects of aging
Peter R., H. (1979) · Brain Research · doi:10.1016/0006-8993(79)90349-4 · Cited by 2,645
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Kalivas, P. W., & Stewart, J. (1991) · Brain Research Reviews · doi:10.1016/0165-0173(91)90007-u · Cited by 2,019
Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?
Feinberg, I. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90038-3 · Cited by 1,395
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., & Greenberg, D. (1974) · Science · doi:10.1126/science.184.4143.1243 · Cited by 834
Research works printed but not linked: 38
- Akbarian, 1993, Psychiatry, 3, 77
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington, D.C., 1994.
- Bracha, 1991, Psychiatry, 30, 25
- Breier, 1997, Sci, 94, 74
- Brenner, 1990, J, 4, 60
- Chakos, 1996, Psychiatry, 4, 9
- Charney, 1993, Psychiatry, 50, 294
- Davis, 1991, Psychiatry, 11, 86
- DeLisi, 1991, Psychiatry, 2, 75
- Done, 1994, A., 309, 699
- Falloon, 1996, J, 2, 82
- Gur, 1995, Psychiatry, 52, 67
- Illowsky, 1998, J Neurol Neurosurg Psychiat, 2, 13
- Kane, 1991, Psychiatry, 47, 90
- Kovelman, 1984, Psychiatry, 12, 211
- Laruelle, 1996, Sci, 17, 40
- Lieberman, 1996, A, 3, 13
- Lieberman, 1993, Psychiatry, 50, 75
- Lieberman, 1994, A, 2, 18
- Lieberman, 1990, A, 1, 97
- Lieberman JA, Sheitman BB, Kinon BJ. Endogenous neurochemical sensitization in the pathophysiology of schizophrenia deficits and dysfunction in neuronol regulation and plasticity. Neuropsychopharmacology, In press.
- Loebel, 1992, Psychiatry, 9, 1183
- Marder, 1994, Psychiatry, 6, 35
- May, 1981, Psychiatry, 38, 84
- McGlashan, 1993, Subtype Progression and Pathophysiologic Deterioration in Early Schizophrenia. Schizophr Bull, 1, 71
- McGlashan, 1996, J, 2, 22
- Meltzer, 1976, A, 2, 19
- Murray, 1992, A, 2, 32
- Nasrallah, 1986, Psychiatry, 43, 9
- Olney, 1995, Psychiatry, 52, 998
- Post, 1976, Psychiatry, 6, 34
- Safferman, 1991, A, 2, 61
- Sato, 1992, Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull, 18, 22
- Tollefson, 1997, Psychiatry, 154, 65
- Von, 1971, J Pharmacol Exp Ther, 194, 52
- Walker, 1990, Psychiatry, 8, 6
- Woods, 1990, Psychiatry, 27, 52
- Zubin, 1997, A, 2, 26
Cited by
Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,593
“It has been postulated that untreated psychosis has a toxic effect through some unknown neurologic or psychological mechanism so that patients with a longer DUP have a poorer prognosis.(2) If this proposition is correct, then reducing DUP through earlier detection and treatment should improve outcome.”
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Early intervention for psychosis
Marshall, M., & Rathbone, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004718.pub3 · Cited by 531
The topography of grey matter involvement in early and late onset Alzheimer's disease
Frisoni, G. B., Pievani, M., Testa, C., Sabattoli, F., Bresciani, L., Bonetti, M., Beltramello, A., Hayashi, K. M., Toga, A. W., & Thompson, P. M. (2007) · Brain · doi:10.1093/brain/awl377 · Cited by 435
“In other neuropsychiatric diseases, e.g. schizophrenia , the earlier onset form is also typically associated with poorer outcomes and refractoriness to treatment (Sheitman and Lieberman, 1998).”
BackgroundNeural development, cell-cell signaling, and the “two-hit” hypothesis of schizophrenia
Maynard, T. M., Sikich, L., Lieberman, J. A., & LaMantia, A.-S. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006887 · Cited by 383
“These subsequent symptoms are resistant to treatment and more likely to recur (Loebel et al. 1992; Lieberman et al. 1996; Sheitman and Lieberman 1998; Robinson et al. 1999).”
Self-citation
Metadata
- Authors
- Sheitman, B. B., & Lieberman, J. A.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Sheitman, B.B
- Venue
- Journal of Psychiatric Research
- Publisher
- Elsevier BV
- Published
- 1998-05
- Volume
- 32
- Issue
- 3-4
- Pages
- 143-150
- ISSN
- 0022-3956 (ISSN-L)
- OpenAlex
- W2067217122
- Cited by
- 140
- References
- 32
- Citations by year
- 2025: 5 · 2024: 8 · 2023: 2 · 2022: 7 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 3 · 2017: 8 · 2016: 8 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 4
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Psychiatric Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH00537, MH 33127)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- treatment-resistant schizophrenia, antipsychotic treatment response, duration of untreated psychosis, behavioral sensitization, dopamine release, limbic striatum, relapse, remission, long-term outcomes, maintenance therapy, early intervention
- MeSH terms
- Brain, Humans, Schizophrenia, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The natural history and pathophysiology of treatment resistant schizophrenia. https://app.cochat.ai/papers/10.1016/s0022-3956(97)00052-6
- The paper
- Sheitman, B. B., & Lieberman, J. A. (1998). The natural history and pathophysiology of treatment resistant schizophrenia. Journal of Psychiatric Research. https://doi.org/10.1016/s0022-3956(97)00052-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.